Masashi Idogawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masashi Idogawa has a total of 360 co-authors. Here are the top co-authors by number of shared publications:
- Yasushi Sasaki
Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University, Sapporo, Japan
33 shared publications - Takashi Tokino
Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
30 shared publications Takashi Tokino
Division of Medical Genome Sciences, Department of Genomic and Preventive Medicine Sapporo Medical University School of Medicine Sapporo Japan
20 shared publicationsKohzoh Imai
The University of Tokyo
13 shared publicationsHiroshi Nakase
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
11 shared publicationsHiromu Suzuki
Department of Molecular Biology, Sapporo Medical University, Sapporo, Japan
10 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Sparfloxacin reveals a host–virus dual-target antiviral scaffold against respiratory syncytial virus
Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness across the lifespan, particularly in infants and older adults. Nonetheless, effective antiviral therapies remain limited. Here, we performed a clinically guided, medium-throughput screening of approved drugs used in pediatric populations and identified sparfloxacin (SPFX), a fluoroquinolone antibiotic, as a mechanistically informative antiviral scaffold. SPFX showed antiviral activity against genetically distinct RSV clinical isolates in vitro, and suppressed RSV infection in a mechanistic mouse model in vivo. Mechanistically, our findings support a host–virus dual-target framework in which SPFX suppresses RSV replication through activity consistent with modulation of viral RNA polymerase function together with a pro-viral HSP70-associated host pathway. Using primary human pediatric airway epithelial cells, we identified SPFX-responsive host factors and observed suppression of HSP70 expression independent of infection. Together, these findings establish SPFX as a mechanistically informative antiviral scaffold and support a host–virus dual-target framework for future RSV therapeutic development.
- 8 August 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessSparfloxacin reveals a host–virus dual-target antiviral scaffold against respiratory syncytial virus
Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness across the lifespan, particularly in infants and older adults. Nonetheless, effective antiviral therapies remain limited. Here, we performed a clinically guided, medium-throughput screening of approved drugs used in pediatric populations and identified sparfloxacin (SPFX), a fluoroquinolone antibiotic, as a mechanistically informative antiviral scaffold. SPFX showed antiviral activity against genetically distinct RSV clinical isolates in vitro, and suppressed RSV infection in a mechanistic mouse model in vivo. Mechanistically, our findings support a host–virus dual-target framework in which SPFX suppresses RSV replication through activity consistent with modulation of viral RNA polymerase function together with a pro-viral HSP70-associated host pathway. Using primary human pediatric airway epithelial cells, we identified SPFX-responsive host factors and observed suppression of HSP70 expression independent of infection. Together, these findings establish SPFX as a mechanistically informative antiviral scaffold and support a host–virus dual-target framework for future RSV therapeutic development.
- Open Access
- 24 July 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Varporter: a software platform for comprehensive genomic profiling (CGP) in cancer
The use of comprehensive genomic profiling (CGP) in cancer, also known as cancer gene panel tests, continues to expand; however, the interpretation of the results of these tests requires a tremendous amount of manual work. To improve the efficiency of this evaluation process, we developed the CGP support software named Varporter. This software automatically imports multiple data files and can display various information contained within the CGP results. In tumor-only tests, TP53 variants often require pathogenicity evaluation as presumed germline pathogenic variants. Varporter enables the automated determination of several criteria in the Variant Interpretation Guidelines established by the ClinGen TP53 Variant Curation Expert Panel. Direct links to the websites on therapeutic evidence are also automatically generated from each variant, and multiple test reports can be summarized onto a single sheet, thus making it easy to review newly added variants to clinical trials. Varporter has made it possible to automate and streamline complicated manual tasks related to CGP evaluation and to redirect human resources to more essential tasks. Varporter is designed for use with two CGP tests covered by Japanese national health insurance, FoundationOne CDx and Guardant360 CDx.
- 24 July 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Open AccessVarporter: a software platform for comprehensive genomic profiling (CGP) in cancer
The use of comprehensive genomic profiling (CGP) in cancer, also known as cancer gene panel tests, continues to expand; however, the interpretation of the results of these tests requires a tremendous amount of manual work. To improve the efficiency of this evaluation process, we developed the CGP support software named Varporter. This software automatically imports multiple data files and can display various information contained within the CGP results. In tumor-only tests, TP53 variants often require pathogenicity evaluation as presumed germline pathogenic variants. Varporter enables the automated determination of several criteria in the Variant Interpretation Guidelines established by the ClinGen TP53 Variant Curation Expert Panel. Direct links to the websites on therapeutic evidence are also automatically generated from each variant, and multiple test reports can be summarized onto a single sheet, thus making it easy to review newly added variants to clinical trials. Varporter has made it possible to automate and streamline complicated manual tasks related to CGP evaluation and to redirect human resources to more essential tasks. Varporter is designed for use with two CGP tests covered by Japanese national health insurance, FoundationOne CDx and Guardant360 CDx.
- Open Access
- 21 January 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Updated analysis of pathogenic variants in BRCA1/BRCA2 among the general Japanese population
Recently, the Tohoku Medical Megabank Organization released whole-genome allele frequencies of single-nucleotide variants and indels from approximately 60,000 individuals from the general Japanese population in the Tohoku region (60KJPN). Here we analyzed the 60KJPN dataset for BRCA1 / BRCA2 variants and compared them with the previous version, 54KJPN, to ascertain the frequency of hereditary breast and ovarian cancers in the general Japanese population. We hope that these results will contribute to strategies for cancer prevention.
- 21 January 2026
- Published by Springer Nature in Human Genome Variation
- Vol. 13 (1)
Open AccessUpdated analysis of pathogenic variants in BRCA1/BRCA2 among the general Japanese population
Recently, the Tohoku Medical Megabank Organization released whole-genome allele frequencies of single-nucleotide variants and indels from approximately 60,000 individuals from the general Japanese population in the Tohoku region (60KJPN). Here we analyzed the 60KJPN dataset for BRCA1 / BRCA2 variants and compared them with the previous version, 54KJPN, to ascertain the frequency of hereditary breast and ovarian cancers in the general Japanese population. We hope that these results will contribute to strategies for cancer prevention.
- Open Access
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1) , 9990671
Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study
Background and Aims: Personalized medicine utilizing comprehensive cancer genomic profiling (CGP) for gynecologic cancers is still in its early stages and faces numerous challenges. In this study, we aimed to elucidate the current status of CGP for gynecologic cancers at our institution. Methods: We prospectively analyzed 44 cases of gynecologic cancers that underwent CGP (FoundationOne CDx or Liquid CDx) from March 2020 to July 2022, evaluating the CGP results and clinical outcomes. Results: Forty‐one cases underwent FoundationOne CDx and four underwent FoundationOne Liquid CDx testing. The distribution of cancer types consisted of 10 cases of cervical cancer, 21 cases of ovarian cancer, 7 cases of endometrial cancer, and 6 cases of sarcomas. Actionable genomic alterations were identified in 42 cases (95.5%), with 16 cases (36.4%) presenting clinically for genotype‐matched therapy (GMT). However, GMT was administered in only three cases (6.8%). Among the cases without GMT, four experienced a deterioration in overall physical condition and two had complications as the reason for nonimplementation. Consideration of presumed germline pathogenic variants occurred in 10 cases (22.2%), with confirmatory testing conducted in two. In survival analysis using the Cox proportional hazards model, the presence of PIK3CA mutations was identified as being potentially associated with adverse prognosis (hazard ratio: 2.73, 95% confidence interval: 1.15–6.49, and p = 0.023). Conclusion: To enhance the prognosis of gynecologic cases, earlier CGP testing to expand the opportunities for GMT and the proactive introduction of PIK3CA ‐related clinical trials might be crucial.
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1) , 9990671
Open AccessEarlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study
Background and Aims: Personalized medicine utilizing comprehensive cancer genomic profiling (CGP) for gynecologic cancers is still in its early stages and faces numerous challenges. In this study, we aimed to elucidate the current status of CGP for gynecologic cancers at our institution. Methods: We prospectively analyzed 44 cases of gynecologic cancers that underwent CGP (FoundationOne CDx or Liquid CDx) from March 2020 to July 2022, evaluating the CGP results and clinical outcomes. Results: Forty‐one cases underwent FoundationOne CDx and four underwent FoundationOne Liquid CDx testing. The distribution of cancer types consisted of 10 cases of cervical cancer, 21 cases of ovarian cancer, 7 cases of endometrial cancer, and 6 cases of sarcomas. Actionable genomic alterations were identified in 42 cases (95.5%), with 16 cases (36.4%) presenting clinically for genotype‐matched therapy (GMT). However, GMT was administered in only three cases (6.8%). Among the cases without GMT, four experienced a deterioration in overall physical condition and two had complications as the reason for nonimplementation. Consideration of presumed germline pathogenic variants occurred in 10 cases (22.2%), with confirmatory testing conducted in two. In survival analysis using the Cox proportional hazards model, the presence of PIK3CA mutations was identified as being potentially associated with adverse prognosis (hazard ratio: 2.73, 95% confidence interval: 1.15–6.49, and p = 0.023). Conclusion: To enhance the prognosis of gynecologic cases, earlier CGP testing to expand the opportunities for GMT and the proactive introduction of PIK3CA ‐related clinical trials might be crucial.
- Open Access
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti–B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody–drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome management, and the bispecific antibody emicizumab has transformed prophylaxis in hemophilia A. Furthermore, novel antibody formats such as the trifunctional anti-CD38 × CD3 antibody (Tri-31C2) exhibit enhanced anti-myeloma activity compared to chimeric CD38 antibodies, underscoring the future potential of T-cell–redirecting designs. This review summarizes key developments in therapeutic antibodies for hematological disorders, their action mechanisms, and emerging strategies to further optimize their efficacy and safety.
Open AccessTherapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti–B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody–drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome management, and the bispecific antibody emicizumab has transformed prophylaxis in hemophilia A. Furthermore, novel antibody formats such as the trifunctional anti-CD38 × CD3 antibody (Tri-31C2) exhibit enhanced anti-myeloma activity compared to chimeric CD38 antibodies, underscoring the future potential of T-cell–redirecting designs. This review summarizes key developments in therapeutic antibodies for hematological disorders, their action mechanisms, and emerging strategies to further optimize their efficacy and safety.
- Open Access
- 27 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11474
Pan-Cancer Analysis Reveals AEBP1-Collagen Co-Expression and Its Potential Role in CAF-Mediated Tumor Stiffness
Cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment that promote cancer progression and immune evasion. Adipocyte enhancer-binding protein 1 gene (AEBP1), which encodes aortic carboxypeptidase-like protein (ACLP), has been implicated in tissue remodeling and fibrosis, yet its role in CAF biology across cancers remains poorly understood. Here, we performed a pan-cancer transcriptomic analysis using The Cancer Genome Atlas (TCGA) and found that AEBP1 expression strongly correlates with expression of collagen family genes in the majority of solid tumors. Integration of single-cell RNA-sequencing datasets from breast and pancreatic cancers revealed that AEBP1 is predominantly expressed in CAFs, where it is co-expressed with collagens and CAF marker genes. Functional experiments using three-dimensional (3D) spheroids composed of oral squamous cell carcinoma (OSCC)-derived CAFs showed that AEBP1 knockdown significantly reduced spheroid stiffness without altering their morphology or size, indicating that ACLP contributes to the mechanical properties of tumor tissues. Together with earlier findings linking AEBP1/ACLP to reduced CD8+ T-cell infiltration, our results suggest that stromal AEBP1/ACLP enhances both extracellular matrix stiffness and immune suppression and highlights AEBP1/ACLP as a potential therapeutic target through which to remodel the tumor microenvironment and improve anti-tumor immunity.
- 27 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11474
Open AccessPan-Cancer Analysis Reveals AEBP1-Collagen Co-Expression and Its Potential Role in CAF-Mediated Tumor Stiffness
Cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment that promote cancer progression and immune evasion. Adipocyte enhancer-binding protein 1 gene (AEBP1), which encodes aortic carboxypeptidase-like protein (ACLP), has been implicated in tissue remodeling and fibrosis, yet its role in CAF biology across cancers remains poorly understood. Here, we performed a pan-cancer transcriptomic analysis using The Cancer Genome Atlas (TCGA) and found that AEBP1 expression strongly correlates with expression of collagen family genes in the majority of solid tumors. Integration of single-cell RNA-sequencing datasets from breast and pancreatic cancers revealed that AEBP1 is predominantly expressed in CAFs, where it is co-expressed with collagens and CAF marker genes. Functional experiments using three-dimensional (3D) spheroids composed of oral squamous cell carcinoma (OSCC)-derived CAFs showed that AEBP1 knockdown significantly reduced spheroid stiffness without altering their morphology or size, indicating that ACLP contributes to the mechanical properties of tumor tissues. Together with earlier findings linking AEBP1/ACLP to reduced CD8+ T-cell infiltration, our results suggest that stromal AEBP1/ACLP enhances both extracellular matrix stiffness and immune suppression and highlights AEBP1/ACLP as a potential therapeutic target through which to remodel the tumor microenvironment and improve anti-tumor immunity.
- Open Access
- 22 October 2025
- Published by MDPI AG in Preprints.org
Pan-Cancer Analysis Reveals AEBP1-Collagen Co-Expression and Its Potential Role in CAF-Mediated Tumor Stiffness
Cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment that promote cancer progression and immune evasion. Adipocyte enhancer-binding protein 1 gene (AEBP1), which encodes aortic carboxypeptidase-like protein (ACLP), has been implicated in tissue remodeling and fibrosis, yet its role in CAF biology across cancers remains poorly understood. Here, we performed a pan-cancer transcriptomic analysis using The Cancer Genome Atlas (TCGA) and found that AEBP1 expression strongly correlates with expression of collagen family genes in a majority of solid tumors. Integration of single-cell RNA-sequencing datasets from breast and pancreatic cancers revealed that AEBP1 is predominantly expressed in CAFs, where it is co-expressed with collagens and CAF marker genes. Functional experiments using three-dimensional (3D) spheroids composed of oral squamous cell carcinoma (OSCC)-derived CAFs showed that AEBP1 knockdown significantly reduced spheroid stiffness without altering their morphology or size, indicating that ACLP contributes to the mechanical properties of tumor tissues. Together with earlier findings linking AEBP1/ACLP to reduced CD8+ T-cell infiltration, our results suggest that stromal AEBP1/ACLP enhances both extracellular matrix stiffness and immune suppression and highlights AEBP1/ACLP as a potential therapeutic target through which to remodel the tumor microenvironment and improve anti-tumor immunity.
- 22 October 2025
- Published by MDPI AG in Preprints.org
Open AccessPan-Cancer Analysis Reveals AEBP1-Collagen Co-Expression and Its Potential Role in CAF-Mediated Tumor Stiffness
Cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment that promote cancer progression and immune evasion. Adipocyte enhancer-binding protein 1 gene (AEBP1), which encodes aortic carboxypeptidase-like protein (ACLP), has been implicated in tissue remodeling and fibrosis, yet its role in CAF biology across cancers remains poorly understood. Here, we performed a pan-cancer transcriptomic analysis using The Cancer Genome Atlas (TCGA) and found that AEBP1 expression strongly correlates with expression of collagen family genes in a majority of solid tumors. Integration of single-cell RNA-sequencing datasets from breast and pancreatic cancers revealed that AEBP1 is predominantly expressed in CAFs, where it is co-expressed with collagens and CAF marker genes. Functional experiments using three-dimensional (3D) spheroids composed of oral squamous cell carcinoma (OSCC)-derived CAFs showed that AEBP1 knockdown significantly reduced spheroid stiffness without altering their morphology or size, indicating that ACLP contributes to the mechanical properties of tumor tissues. Together with earlier findings linking AEBP1/ACLP to reduced CD8+ T-cell infiltration, our results suggest that stromal AEBP1/ACLP enhances both extracellular matrix stiffness and immune suppression and highlights AEBP1/ACLP as a potential therapeutic target through which to remodel the tumor microenvironment and improve anti-tumor immunity.
- Open Access
- 1 October 2025
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 14, 107-116
Upregulation of LINC02154 promotes esophageal cancer progression by enhancing cell cycling and epithelial-mesenchymal transition
Long noncoding RNAs (lncRNAs) play crucial roles in the progression of human malignancies; however, their involvement in esophageal cancer (ESCA) remains incompletely understood. In this study, we screened for lncRNAs upregulated in ESCA and identified 12 lncRNAs significantly upregulated in primary ESCA tumors. Among those, elevated LINC02154 expression correlated positively with advanced T stages. LINC02154 knockdown in ESCA cell lines suppressed cell proliferation and migration, while ectopic expression of LINC02154 enhanced colony formation. Depletion of LINC02154 suppressed genes involved in various oncogenic processes, including cell cycling, epithelial-mesenchymal transition (EMT), and metabolism. We also found that LINC02154 promotes EMT and enhances chemoresistance, at least in part, through suppression of miR-200b. Finally, RNA-pulldown and mass spectrometry analysis revealed that LINC02154 interacts with proteins involved in the cornified envelope or desmosome. These findings suggest that LINC02154 exerts oncogenic effects through modulation of multiple oncogenic signaling pathways in ESCA and that LINC02154 is a potential therapeutic target.
- 1 October 2025
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 14, 107-116
Open AccessUpregulation of LINC02154 promotes esophageal cancer progression by enhancing cell cycling and epithelial-mesenchymal transition
Long noncoding RNAs (lncRNAs) play crucial roles in the progression of human malignancies; however, their involvement in esophageal cancer (ESCA) remains incompletely understood. In this study, we screened for lncRNAs upregulated in ESCA and identified 12 lncRNAs significantly upregulated in primary ESCA tumors. Among those, elevated LINC02154 expression correlated positively with advanced T stages. LINC02154 knockdown in ESCA cell lines suppressed cell proliferation and migration, while ectopic expression of LINC02154 enhanced colony formation. Depletion of LINC02154 suppressed genes involved in various oncogenic processes, including cell cycling, epithelial-mesenchymal transition (EMT), and metabolism. We also found that LINC02154 promotes EMT and enhances chemoresistance, at least in part, through suppression of miR-200b. Finally, RNA-pulldown and mass spectrometry analysis revealed that LINC02154 interacts with proteins involved in the cornified envelope or desmosome. These findings suggest that LINC02154 exerts oncogenic effects through modulation of multiple oncogenic signaling pathways in ESCA and that LINC02154 is a potential therapeutic target.
- 30 September 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (6) , e70056
Fusion Gene Detection in Driver Mutation‐Negative Melanomas Using RNA ‐Based Anchored Multiplex Polymerase Chain Reaction
Advanced melanoma is typically treated with immune checkpoint inhibitors (ICIs) and targeted therapies. However, their efficacy is limited in acral and mucosal melanomas, which are more prevalent in non‐White populations and often exhibit low tumor mutational burden and lack BRAF mutations. Fusion genes, widely used as therapeutic targets in other cancers, may represent alternative targets in these melanoma subtypes. This study aimed to detect fusion genes in Japanese melanomas lacking major driver mutations ( BRAF , RAS , NF1 , or KIT ) using a custom RNA‐based anchored multiplex polymerase chain reaction (AMP) panel. RNA extracted from 14 tumors, primarily formalin‐fixed paraffin‐embedded specimens, was analyzed using a custom Archer FUSIONPlex panel. Libraries were successfully generated in 80% of cases, and two in‐frame fusions— MAD1L1 :: BRAF and CIC :: MEGF8 —were identified (17%). MAD1L1 :: BRAF retained the BRAF kinase domain and may be targetable by MEK inhibitors. CIC :: MEGF8 , a novel fusion in melanoma, may result in transcriptional dysregulation through CIC loss of function. This Method paper outlines the AMP workflow, including troubleshooting strategies and quality control criteria, and demonstrates its applicability to clinical samples. Our findings support the utility of RNA‐based fusion detection in driver‐negative melanomas and the potential of fusion genes as actionable targets.
- 30 September 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (6) , e70056
Fusion Gene Detection in Driver Mutation‐Negative Melanomas Using RNA ‐Based Anchored Multiplex Polymerase Chain Reaction
Advanced melanoma is typically treated with immune checkpoint inhibitors (ICIs) and targeted therapies. However, their efficacy is limited in acral and mucosal melanomas, which are more prevalent in non‐White populations and often exhibit low tumor mutational burden and lack BRAF mutations. Fusion genes, widely used as therapeutic targets in other cancers, may represent alternative targets in these melanoma subtypes. This study aimed to detect fusion genes in Japanese melanomas lacking major driver mutations ( BRAF , RAS , NF1 , or KIT ) using a custom RNA‐based anchored multiplex polymerase chain reaction (AMP) panel. RNA extracted from 14 tumors, primarily formalin‐fixed paraffin‐embedded specimens, was analyzed using a custom Archer FUSIONPlex panel. Libraries were successfully generated in 80% of cases, and two in‐frame fusions— MAD1L1 :: BRAF and CIC :: MEGF8 —were identified (17%). MAD1L1 :: BRAF retained the BRAF kinase domain and may be targetable by MEK inhibitors. CIC :: MEGF8 , a novel fusion in melanoma, may result in transcriptional dysregulation through CIC loss of function. This Method paper outlines the AMP workflow, including troubleshooting strategies and quality control criteria, and demonstrates its applicability to clinical samples. Our findings support the utility of RNA‐based fusion detection in driver‐negative melanomas and the potential of fusion genes as actionable targets.
- Open Access
- 8 February 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 275-284
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study
Ten-eleven translocation-2 (TET2) gene mutations are observed in 12–20% of adult patients with acute myeloid leukemia (AML). The prognostic impact of TET2 mutations in patients with AML and myelodysplastic syndromes has been reported in several studies; however, their results remain controversial. Therefore, we aimed to analyze the prevalence and significance of TET2 mutations in patients with AML. Data were obtained from 331 patients with AML according to the Hematologic Malignancies-SCREEN-Japan 01 and 02 studies, which were prospective multicenter genomic profiling analyses. We found a distinct type of TET2 mutations, with a particularly detrimental prognosis in the patients. Thirty-five patients with TET2 ‘significant’ mutations were identified (26 with frameshift mutations and nine with nonsense mutations). The proportion of patients with TET2 mutations was 31.7% (10.6% and 21.1% in the TET2 significant and non-significant mutation groups). The TET2 significant mutation group had a shorter OS than the TET2 non-significant mutation or wild-type TET2 group (median: 15.9 vs. 35.0 vs. 25.9 months). Regarding the response to chemotherapy according to TET2 status, the complete response (CR) or CR with incomplete count recovery rate was 37.1% in the TET2 significant mutation group and 46.6% in the non-significant mutation or wild-type group. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved patient prognosis in the TET2 non-significant mutation or wild-type TET2 group; however, allo-HSCT did not affect prognosis in the TET2 significant mutation group. This study indicates that certain TET2 mutations in patients with AML may have detrimental effects.
- 8 February 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 275-284
Open AccessPrognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study
Ten-eleven translocation-2 (TET2) gene mutations are observed in 12–20% of adult patients with acute myeloid leukemia (AML). The prognostic impact of TET2 mutations in patients with AML and myelodysplastic syndromes has been reported in several studies; however, their results remain controversial. Therefore, we aimed to analyze the prevalence and significance of TET2 mutations in patients with AML. Data were obtained from 331 patients with AML according to the Hematologic Malignancies-SCREEN-Japan 01 and 02 studies, which were prospective multicenter genomic profiling analyses. We found a distinct type of TET2 mutations, with a particularly detrimental prognosis in the patients. Thirty-five patients with TET2 ‘significant’ mutations were identified (26 with frameshift mutations and nine with nonsense mutations). The proportion of patients with TET2 mutations was 31.7% (10.6% and 21.1% in the TET2 significant and non-significant mutation groups). The TET2 significant mutation group had a shorter OS than the TET2 non-significant mutation or wild-type TET2 group (median: 15.9 vs. 35.0 vs. 25.9 months). Regarding the response to chemotherapy according to TET2 status, the complete response (CR) or CR with incomplete count recovery rate was 37.1% in the TET2 significant mutation group and 46.6% in the non-significant mutation or wild-type group. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved patient prognosis in the TET2 non-significant mutation or wild-type TET2 group; however, allo-HSCT did not affect prognosis in the TET2 significant mutation group. This study indicates that certain TET2 mutations in patients with AML may have detrimental effects.